trending Market Intelligence /marketintelligence/en/news-insights/trending/qLkena3BKCvO8YuOGgz1_Q2 content esgSubNav
In This List

Cellectar Biosciences secures patent for radiotherapy compounds

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Cellectar Biosciences secures patent for radiotherapy compounds

Cellectar Biosciences Inc. secured patents covering the method of use for its CLR 131 and CLR 125 compounds in radiotherapy in the U.S.

The patent runs through 2025 and covers radiotherapy applications for multiple tumor types, including lung and intestinal.

Cellectar also recently received a patent covering the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers, as well as associated cancer stem cells.